AR and prostate neoplasm: For example, EZH2-S21phospho may reduce EZH2 binding to histone H3 [56] and enhance its interactions to non-PRC2 partners, such as androgen receptor (AR) in advanced prostate tumor and STAT3 in GBM (Figure 3a and Table 2).